Clinical Trial Update: A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating radiation exposure to organs and the safety of CARDIOLITE in pediatric patients with Kawasaki disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kawasaki Disease

Drugs mentioned

• CARDIOLITE (TETRAKIS(2-METHOXYISOBUTYLISOCYANIDE)COPPER(I) TETRAFLUOROBORATE)

Snippet

Sponsor: Lantheus Medical Imaging | Conditions: Kawasaki Disease | Phase 1, Phase 2 | Status: COMPLETED